Are growth factors leukemogenic?

Research output: Contribution to journalArticle

Abstract

The National Cancer Institute (NCI) recently alerted clinicians to the possibility that patients, entered on a NCI-sponsored cooperative group trial of doxorubicin and cyclophosphamide adjuvant therapy for breast cancer, may be at high risk of developing secondary acute myeloid leukemia (AML). Secondary AML following standard doses of doxorubicin and cyclophosphamide is uncommon, suggesting that the high risk on this trial may result from its higher-than-standard doses of chemotherapy. However, the cases of secondary AML were characteristic of the type that follows treatment with topoisomerase II-active agents, especially etoposide, and this type of secondary AML is rare after treatment with either cyclophosphamide or doxorubicin at any dose. We raise the possibility that another component of this trial, hematopoietic growth factors to decrease the toxicities related to myelosuppression, may play an important role in the development of secondary AML. Growth factors not only stimulate hematopoietic progenitor proliferation and differentiation, they also regulate hematopoietic cell survival by interfering with apoptosis (programmed cell death). Inhibition of apoptosis by a variety of genetic factors is an important mechanism of oncogenesis, and appears to be the initiating event in some malignancies. Growth factor-mediated suppression of the apoptotic death of hematopoietic damaged by chemotherapy may contribute to their leukemic transformation.

Original languageEnglish (US)
Pages (from-to)175-177
Number of pages3
JournalLeukemia
Volume10
Issue number1
StatePublished - Jan 1996

Fingerprint

Acute Myeloid Leukemia
Intercellular Signaling Peptides and Proteins
Doxorubicin
Cyclophosphamide
National Cancer Institute (U.S.)
Apoptosis
Drug Therapy
Type II DNA Topoisomerase
Etoposide
Cell Survival
Carcinogenesis
Cell Death
Therapeutics
Breast Neoplasms
Neoplasms

Keywords

  • Apoptosis
  • Chemotherapy
  • Growth factors
  • Secondary leukemia

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Are growth factors leukemogenic? / Brodsky, Robert A; Bedi, Atul; Jones, Richard J.

In: Leukemia, Vol. 10, No. 1, 01.1996, p. 175-177.

Research output: Contribution to journalArticle

@article{06940da956f547c0bce40c0d085894b7,
title = "Are growth factors leukemogenic?",
abstract = "The National Cancer Institute (NCI) recently alerted clinicians to the possibility that patients, entered on a NCI-sponsored cooperative group trial of doxorubicin and cyclophosphamide adjuvant therapy for breast cancer, may be at high risk of developing secondary acute myeloid leukemia (AML). Secondary AML following standard doses of doxorubicin and cyclophosphamide is uncommon, suggesting that the high risk on this trial may result from its higher-than-standard doses of chemotherapy. However, the cases of secondary AML were characteristic of the type that follows treatment with topoisomerase II-active agents, especially etoposide, and this type of secondary AML is rare after treatment with either cyclophosphamide or doxorubicin at any dose. We raise the possibility that another component of this trial, hematopoietic growth factors to decrease the toxicities related to myelosuppression, may play an important role in the development of secondary AML. Growth factors not only stimulate hematopoietic progenitor proliferation and differentiation, they also regulate hematopoietic cell survival by interfering with apoptosis (programmed cell death). Inhibition of apoptosis by a variety of genetic factors is an important mechanism of oncogenesis, and appears to be the initiating event in some malignancies. Growth factor-mediated suppression of the apoptotic death of hematopoietic damaged by chemotherapy may contribute to their leukemic transformation.",
keywords = "Apoptosis, Chemotherapy, Growth factors, Secondary leukemia",
author = "Brodsky, {Robert A} and Atul Bedi and Jones, {Richard J}",
year = "1996",
month = "1",
language = "English (US)",
volume = "10",
pages = "175--177",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Are growth factors leukemogenic?

AU - Brodsky, Robert A

AU - Bedi, Atul

AU - Jones, Richard J

PY - 1996/1

Y1 - 1996/1

N2 - The National Cancer Institute (NCI) recently alerted clinicians to the possibility that patients, entered on a NCI-sponsored cooperative group trial of doxorubicin and cyclophosphamide adjuvant therapy for breast cancer, may be at high risk of developing secondary acute myeloid leukemia (AML). Secondary AML following standard doses of doxorubicin and cyclophosphamide is uncommon, suggesting that the high risk on this trial may result from its higher-than-standard doses of chemotherapy. However, the cases of secondary AML were characteristic of the type that follows treatment with topoisomerase II-active agents, especially etoposide, and this type of secondary AML is rare after treatment with either cyclophosphamide or doxorubicin at any dose. We raise the possibility that another component of this trial, hematopoietic growth factors to decrease the toxicities related to myelosuppression, may play an important role in the development of secondary AML. Growth factors not only stimulate hematopoietic progenitor proliferation and differentiation, they also regulate hematopoietic cell survival by interfering with apoptosis (programmed cell death). Inhibition of apoptosis by a variety of genetic factors is an important mechanism of oncogenesis, and appears to be the initiating event in some malignancies. Growth factor-mediated suppression of the apoptotic death of hematopoietic damaged by chemotherapy may contribute to their leukemic transformation.

AB - The National Cancer Institute (NCI) recently alerted clinicians to the possibility that patients, entered on a NCI-sponsored cooperative group trial of doxorubicin and cyclophosphamide adjuvant therapy for breast cancer, may be at high risk of developing secondary acute myeloid leukemia (AML). Secondary AML following standard doses of doxorubicin and cyclophosphamide is uncommon, suggesting that the high risk on this trial may result from its higher-than-standard doses of chemotherapy. However, the cases of secondary AML were characteristic of the type that follows treatment with topoisomerase II-active agents, especially etoposide, and this type of secondary AML is rare after treatment with either cyclophosphamide or doxorubicin at any dose. We raise the possibility that another component of this trial, hematopoietic growth factors to decrease the toxicities related to myelosuppression, may play an important role in the development of secondary AML. Growth factors not only stimulate hematopoietic progenitor proliferation and differentiation, they also regulate hematopoietic cell survival by interfering with apoptosis (programmed cell death). Inhibition of apoptosis by a variety of genetic factors is an important mechanism of oncogenesis, and appears to be the initiating event in some malignancies. Growth factor-mediated suppression of the apoptotic death of hematopoietic damaged by chemotherapy may contribute to their leukemic transformation.

KW - Apoptosis

KW - Chemotherapy

KW - Growth factors

KW - Secondary leukemia

UR - http://www.scopus.com/inward/record.url?scp=0030052946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030052946&partnerID=8YFLogxK

M3 - Article

C2 - 8558925

AN - SCOPUS:0030052946

VL - 10

SP - 175

EP - 177

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -